Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.53 |
| ▸ | NOS3 | P29474 | 8/20 | 0.49 |
| ▸ | NOS2 | P35228 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19749952 | 0.81 | NOS1 (0.50) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL3290310 | 0.70 | MEN1 (0.56) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL6643315 | 0.69 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL2515680 | 0.68 | NOS1 (0.38) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL7505121 | 0.67 | NOS1 (0.52) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL6644831 | 0.65 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL6599478 | 0.65 | SIGMAR1 (0.43) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5899578 | 0.62 | IDO1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6642324 | 0.62 | NOS1 (0.58) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL6647611 | 0.62 | NOS1 (0.58) | NOS1NOS3NOS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117656-B1 | GREY COLOURING PHOTOCHROMIC FUSED PYRANS | JAMES ROBINSON LTD (GB) | 2002-05-29 | — | — | EP | claimed |
| US-6387512-B1 | FOR COLORING INKS, FUELS, PLASTICS OR GLASS | JAMES ROBINSON LIMITED (GB) | 2002-05-14 | — | — | US | claimed |
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2024-03-12 | — | — | US | disclosed |
| WO-2024010870-A2 | CRYSTALLINE MONOMERS FOR PREPARING ANTISENSE OLIGONUCLEOTIDES AND METHODS OF THEIR PREPARATION AND USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-01-11 | — | — | WO | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-06-20 | — | — | US | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| EP-3957639-A1 | PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF | Einziger, Michael (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11220491-B2 | Photoprotective compositions containing Malassezia-derived compounds and/or chemical analogs thereof | VERSICOLOR TECHNOLOGIES, LLC (US) | 2022-01-11 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1117656-B1 | GREY COLOURING PHOTOCHROMIC FUSED PYRANS | JAMES ROBINSON LTD (GB) | 2002-05-29 | — | — | EP | disclosed |
| US-6387512-B1 | FOR COLORING INKS, FUELS, PLASTICS OR GLASS | JAMES ROBINSON LIMITED (GB) | 2002-05-14 | — | — | US | disclosed |
| EP-1140892-A1 | PHOTOCHROMIC SUBSTIITUTED 2H-NAPHTHO[1,2-B]PYRANS | JAMES ROBINSON LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140892-A1 | PHOTOCHROMIC SUBSTIITUTED 2H-NAPHTHO[1,2-B]PYRANS | JAMES ROBINSON LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1117656-A1 | GREY COLOURING PHOTOCHROMIC FUSED PYRANS | JAMES ROBINSON LIMITED (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000035902-A1 | PHOTOCHROMIC SUBSTITUTED 2H-NAPHTHO[1,2-b]PYRANS | JAMES ROBINSON LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035902-A1 | PHOTOCHROMIC SUBSTITUTED 2H-NAPHTHO[1,2-b]PYRANS | JAMES ROBINSON LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000018755-A1 | GREY COLOURING PHOTOCHROMIC FUSED PYRANS | JAMES ROBINSON LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | PLAAT5, PLAAT3, SNRPE | NOS1 4741/4885NOS3 4521/4885NOS2 4699/4885 |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | NOS1 4640/4885NOS3 4401/4885NOS2 4594/4885 |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | NOS1 3588/4885NOS3 3139/4885NOS2 3410/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | NOS1 1877/4885NOS3 1291/4885NOS2 2305/4885 |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | NOS1 2695/4885NOS3 2815/4885NOS2 2872/4885 |
| US-11220491-B2 | Photoprotective compositions containing Malassezia-derived compounds and/or chemical analogs thereof | TYR, AHR, MC1R | NOS1 2620/4885NOS3 1985/4885NOS2 1830/4885 |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | PLAAT5, PLAAT3, PLAAT4 | NOS1 4621/4885NOS3 4329/4885NOS2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.